All AbMole products are for research use only, cannot be used for human consumption.
AZD1152-HQPA (Barasertib) is a highly potent and selective inhibitor of Aurora with Ki values of 0.36 and 1369 nM for Aurora B and Aurora A respectively.Consistent with inhibition of Aurora B kinase, addition of AZD1152-HQPA to tumor cells in vitro induces chromosome misalignment, prevents cell division, and consequently reduces cell viability and induces apoptosis.
Int J Mol Sci. 2023 Mar 6;24(5):5016.
Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas
AZD1152-HQPA purchased from AbMole
J Hematol Oncol. 2017 Jun 8;10(1):115.
SIX3, a tumor suppressor, inhibits astrocytoma tumorigenesis by transcriptional repression of AURKA/B.
AZD1152-HQPA purchased from AbMole
. figure 7..jpg) |
Source | Journal of Hematology & Oncology (2017). Figure 7. AZD1152-HQPA (Abmole Bioscience) |
| Method | CCK8 assay | |
| Cell Lines | U251, U87 and U118 cell lines | |
| Concentrations | ||
| Incubation Time | 48 h | |
| Results | Treatment with two other aurora kinase inhibitors, AZD1152 and MLN8237, demonstrated similar results (Fig. 7d). |
| Cell Experiment | |
|---|---|
| Cell lines | HL-60 and U937 cells line |
| Preparation method | Proliferation assay. To evaluate the growth inhibition effects, the sodium 3′-(1-[(phenylamino)-carbonyl-3,4-tetrazolium])-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate (XTT) assay was performed according to the manufacturer’s instructions (AbMole) with slight modifications. Cell cycle distribution. Flow cytometric analysis was performed to evaluate the cell cycle distribution. The treated samples were fixed in 80% ethanol, stained with 20 ng/mL propidium iodide (AbMole, M5108), and analyzed using FACSCanto II. |
| Concentrations | 25 nM |
| Incubation time | 0 h, 24 h, 48 h, and 72 h |
| Animal Experiment | |
|---|---|
| Animal models | SW620, Colo205, HCT116 human colorectal tumor xenografts in nude mice |
| Formulation | in Tris buffer pH 9.0 |
| Dosages | 150 mg/kg/day |
| Administration | subcutaneous infusion |
| Molecular Weight | 507.56 |
| Formula | C26H30FN7O3 |
| CAS Number | 722544-51-6 |
| Solubility (25°C) | DMSO ≥ 50 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Aurora Kinase Products |
|---|
| Phthalazinone pyrazole
Phthalazinone pyrazole is a potent, selective, and orally active inhibitor of Aurora-A kinase with an IC50 of 0.031 μM. |
| Aurora Kinases-IN-4
Aurora Kinases-IN-4 is a covalent and ATP competitive aurora kinase A inhibitor (IC50: 1.7 nM). |
| Derrone
Derrone, a prenylated isoflavones, is an Aurora kinase inhibitor, with IC50 values of 6 and 22.3 μM against Aurora B and Aurora A, respectively. Derrone shows anti-tumor activity. |
| CD532 hydrochloride
CD532 hydrochloride is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 hydrochloride has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 hydrochloride also can directly interact with AURKA and induces a global conformational shift. CD532 hydrochloride can be used for the research of cancer. |
| Aurora kinase inhibitor-2
Aurora kinase inhibitor-2 is a selective and ATP-competitive Aurora kinase inhibitor with IC50s of 310 nM and 240 nM for Aurora A and Aurora B, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
